Manufacturing Strategy & Operating Model
The role a site plays in the network and how it is set up to play it — technology choice, campaign versus dedicated operation, shift and organisational model, in-house versus contract manufacture — determines which risks the site carries permanently. A campaign model concentrates changeover and cross-contamination risk; a dedicated one concentrates capacity risk. Neither is wrong, but the control burden differs and should be chosen deliberately rather than inherited.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 22 LINKSA manufacturing network is a set of decisions about where risk sits — single-source, internal versus contracted, standardised versus local — and each was defensible alone, which is why the aggregate is rarely examined.
06 · QUALITY MATURITY — MANUFACTURING STRATEGY & OPERATING MODEL, REACTIVE TO ADAPTIVE
The network is what history left. Sites do things differently and nobody can say which differences were chosen.
A strategy document exists describing the intended footprint, and the operating model in practice does not match it.
Roles are defined per site, the differences between them are deliberate and recorded, and the network’s single points of failure are known.
Capacity, capability and continuity are planned together, so a decision to move a product between sites is assessed for what it costs in requalification and knowledge.
The network is arranged so that a site loss is survivable and a product move is routine — which is a property of how it was designed rather than of how it is managed.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 5
Derived from the 5 standards SPEQ maps to this subject, across 4 regulatory bodies: FDA, EMA, ICH, PIC/S.
RECORDS & OBJECTIVE EVIDENCE
- The defined role and scope of each site in the network
- The record of which differences between sites are deliberate and why
- Single-point-of-failure analysis across products, materials and sites
- Capacity and capability data supporting the current allocation of products
- Assessments performed when a product was moved between sites
COMMON INSPECTION FINDINGS
- Sites differing in ways nobody can explain as a decision
- A single site or supplier for a critical product with no continuity assessment
- Products allocated by history rather than by capability, with recurring problems at one site
- A strategy document describing a network that does not exist
- Product moves executed without assessing the knowledge that does not travel with them
Campaign versus dedicated is a control-strategy decision
Multi-product operation on shared equipment is the norm and is entirely acceptable, but it makes cleaning validation the load-bearing control: the acceptance limits derived from health-based exposure limits, the worst-case product matrix, the changeover procedure and its verification are what stand between one product and the next. EU GMP requires dedicated facilities for certain product classes precisely because that control cannot bear the load in every case.
Dedicated operation removes that burden and substitutes another. Capacity is now coupled to a single product’s demand, the line is idle when demand falls, and a single equipment failure has no internal alternative. The strategic decision is which of those risks the organisation is better able to manage — and it should be made explicitly, because the cleaning-validation programme and the continuity plan that follow are large, long-lived commitments.
Network role determines what a site must be good at
A launch site, a high-volume commercial site and a clinical-supply site are different operations wearing similar equipment. The launch site needs to absorb change and run technology transfers well; the commercial site needs stability, yield and consistency; the clinical site needs flexibility across small batches and frequent product changes. Asking one site to be all three produces an operation optimised for none.
The consequence is felt in the quality system rather than the plant. A site that changes constantly needs change control and technology-transfer capability far above the norm; a stable site needs continued process verification and a strong deviation culture. Building the same quality system at both is how one of them ends up under-resourced in exactly the area that determines its performance.
Making it elsewhere does not move the accountability
Contract manufacture changes who performs the work and not who answers for it. The marketing-authorisation holder remains accountable for product quality, which is why the quality agreement, the oversight model and the audit programme matter more than the manufacturing agreement. Oversight that consists of receiving a certificate of analysis is not oversight; it is a transaction.
The operating-model question is how much technical capability to retain when manufacturing is outsourced. Organisations that retain none cannot evaluate a deviation the contract manufacturer reports, cannot assess a proposed process change, and cannot judge whether an investigation reached a root cause. That capability is the price of outsourcing responsibly, and it is usually the first thing cut when the outsourcing case is built.
SPEQ interpretation — the operating model is chosen once and inherited forever
Operating-model decisions are made during a capital case or a network review, using financial and capacity analysis, and the quality consequences are inherited by people who were not in the room. The cleaning-validation programme that a campaign model requires, the continuity exposure a dedicated line creates, the oversight capability outsourcing demands — each is a permanent operational commitment created by a decision framed as strategic.
The practical recommendation is narrow: put the control burden in the decision paper. Not as a risk register entry, but as the specific ongoing programme each option requires and what it costs to run properly. That is information the decision needs and almost never receives, and it is the difference between choosing a model and acquiring one.
FREQUENTLY ASKED
Is multi-product manufacture on shared equipment acceptable?
Generally yes, and it is the norm — but it makes cleaning validation the load-bearing control, with limits derived from health-based exposure limits and a defensible worst-case matrix. EU GMP requires dedicated facilities for certain product classes precisely because that control cannot carry every case.
What does contract manufacture change?
Who performs the work, not who answers for it. The marketing-authorisation holder remains accountable for product quality, which is why the quality agreement, oversight model and audit programme carry more weight than the manufacturing agreement. Receiving a certificate of analysis is a transaction, not oversight.
How much technical capability should be retained when outsourcing?
Enough to evaluate a deviation the contract manufacturer reports, assess a proposed process change, and judge whether an investigation reached a root cause. Organisations that retain none cannot exercise the oversight they remain accountable for — and this capability is usually the first item cut when the outsourcing business case is built.
Should every site in a network run the same quality system?
Not at the same intensity. A launch site absorbing constant change needs change control and technology-transfer capability well above the norm; a stable commercial site needs continued process verification and deviation depth. Building identical systems leaves one of them under-resourced in exactly the area that determines its performance.